CJC-1295 is being sold to athletes and aging adults as a superior growth hormone secretagogue, and the marketing leans heavily on its extended half-life as proof of clinical advantage. The pharmacokinetic elegance of albumin binding is real; the clinical payoff, measured against any outcome a patient would care about, remains entirely undemonstrated. When you set CJC-1295 beside tesamorelin, a GHRH analog that has completed Phase III trials and earned FDA approval, the evidentiary gap is categorical, not a matter of degree.
What the three human studies have shown
The foundational human data for CJC-1295 comes from Teichman et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006. This was a double-blind, placebo-controlled trial in 65 healthy adults aged 21 to 61, and it remains, nearly two decades later, the best evidence available for the compound. [1]
What Teichman and colleagues found was genuinely interesting: a single subcutaneous injection produced dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold, lasting six days or more. That is a pharmacokinetic result worth taking seriously. [1]
What they did not find, because they did not look, was any effect on body composition, bone density, exercise capacity, or any other endpoint that would tell a clinician whether the GH and IGF-1 elevation translated into something useful. The trial was a pharmacokinetics and pharmacodynamics study, not an efficacy trial, and the peptide-promotion industry has been misrepresenting it as the latter ever since.
No published data confirm the specific IGF-1 duration figures (1.5- to 3-fold for 9 to 11 days) that circulate widely in supplement forums, and the albumin-binding half-life of 6 to 8 days that appears in promotional materials lacks a verified primary-source citation in the human literature. The mechanism is biochemically plausible, but plausibility is not data.
Bottom line: CJC-1295 has one well-conducted Phase I/II pharmacokinetic trial in humans. It has zero trials with a clinical endpoint. That is the entire human dataset.
The tesamorelin comparison is not close
Tesamorelin, a stabilized full-length GHRH analog, is what a GHRH-class compound looks like after it has been developed. Its approval rests on a body of Phase III randomised, double-blind, multicentre trial data. A 2019 trial published in The Lancet HIV61 HIV-positive patients with non-alcoholic fatty liver disease, randomised to tesamorelin or placebo for 12 months, found a 37% relative reduction in hepatic fat fraction versus placebo (p=0.016). [2] That is a specific number, in a specific patient population, from a specific controlled trial. The Falutz et al. Phase III trials from 2007 and 2010 enrolled over 800 patients with HIV-associated lipodystrophy and demonstrated statistically significant visceral adipose tissue reduction. [2]
CJC-1295 has no equivalent: no Phase III trial, no regulatory submission, no approval. A 2026 review in Frontiers in Aging describes CJC-1295 as a peptide with “promising but limited clinical evidence” that lacks “systematic validation.” [3] That is a generous framing for a compound whose human evidence consists of a single pharmacokinetic study from 2006.
The comparison to tesamorelin is not meant to suggest that CJC-1295 could not eventually demonstrate clinical efficacy. It illustrates what actual clinical development looks like, and how far CJC-1295 is from it.
Sermorelin: the less glamorous alternative with a better track record
Sermorelin, the first-generation GHRH analog that predates the DAC-modified compounds, gets dismissed by peptide enthusiasts because it requires daily dosing. Its half-life is under 30 minutes. There is no albumin binding, no once-weekly injection, nothing architecturally clever about it.
What sermorelin has is a longer clinical track record in pediatric growth hormone deficiency and a better-characterised safety profile than CJC-1295 in any population. [4] A 2020 review in Translational Andrology and Urology examined sermorelin alongside other GH secretagogues and noted that clinical efficacy data for the class remain limited, but sermorelin’s history of use gives it a safety baseline that CJC-1295 simply does not have. [4]
The once-weekly dosing convenience of CJC-1295 is a real pharmacokinetic advantage. Whether it translates into better clinical outcomes, better adherence, or better safety is unknown, because no comparative trial exists.
Ipamorelin and the combination protocol problem
The most common way CJC-1295 is used off-label is in combination with ipamorelin, a growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor rather than the GHRH receptor. The two are co-administered on the theory that stimulating both pathways simultaneously produces additive or synergistic GH release. The theory is mechanistically reasonable; the clinical evidence for the combination in humans is nonexistent.
Ipamorelin’s published dose-finding work, from Raun et al. in 1998, was conducted at doses of 1 to 1000 mcg/kg in animal models. No published human dose-finding trial for the CJC-1295 and ipamorelin combination has been conducted or registered. [3] The 2026 Frontiers in Aging review identifies this combination as a significant knowledge gap, noting that optimal dosing regimens and combination therapy effects remain uncharacterised. [3]
The combination protocol that is most widely promoted, most actively sold by compounding pharmacies, and most frequently discussed in athlete and longevity communities has no human trial data at any dose, in any population, for any duration. That absence should change how the combination is discussed, and prescribed.
Safety: what we know and what we don’t
What the Teichman trial reported: injection-site reactions and transient facial flushing in a minority of subjects. No serious adverse events were attributed to CJC-1295 in the trial period. That is reassuring as far as it goes, which is not very far given the short follow-up and healthy-volunteer population.
What has never been studied: CJC-1295’s safety in people with insulin resistance, active malignancy, or pituitary pathology. These are not exotic edge cases. They describe a substantial proportion of the adults who are seeking the compound off-label.
The IGF-1 duration concern: CJC-1295 produces sustained IGF-1 elevation over days rather than the transient peaks associated with pulsatile GH secretion. The proliferative risks of chronically elevated IGF-1 are documented in the acromegaly literature, where patients with pathologically elevated GH and IGF-1 show increased rates of colon polyps and other neoplasms. Whether research-dose GHRH analogs produce IGF-1 elevations sufficient to carry that risk is genuinely unknown, theoretical, not established, but theoretical concerns deserve more weight when the compound producing them has no long-term safety data.
A useful cross-domain reference: MK-677 (ibutamoren), an oral ghrelin mimetic that also elevates IGF-1, was studied by Nass et al. in a 2-year RCT in 65 healthy adults aged 60 to 81. Daily oral MK-677 at 25 mg increased IGF-1 to young-adult ranges and increased fat-free mass. It also reduced insulin sensitivity and raised fasting glucose. [5] That two-year dataset, with its documented metabolic trade-offs, is more informative about the class-level risk of sustained IGF-1 elevation than anything published for CJC-1295. The fact that the oral alternative has better long-term safety data than the injectable one should give pause to anyone treating CJC-1295’s short-term tolerability as a safety clearance.
Where clinical development stands
No currently active Phase II or Phase III trials for CJC-1295 appear in public registry records. The compound’s development has not progressed beyond the 2006 Teichman trial in any meaningful way. Meanwhile, tesamorelin has accumulated Phase III data and regulatory approval, and MK-677 has a 2-year RCT with body composition endpoints. [5] [2]
An honest reassessment of CJC-1295’s clinical position would require a head-to-head trial against tesamorelin or sermorelin, with a body composition or functional endpoint, and a follow-up period of at least six months. No such trial has been registered or published.
What exists instead is a compound being produced in unregulated facilities, frequently sourced from overseas manufacturers, and administered to people with no knowledge of what dose they are receiving, no baseline IGF-1 monitoring, and no follow-up. The pharmacokinetic feature that makes CJC-1295 interesting in a research context, that sustained albumin binding, is precisely what makes unsupervised use more concerning. A compound that elevates IGF-1 for nine to eleven days after a single injection does not tolerate casual dosing errors well.
The enthusiasm for CJC-1295 in longevity and performance circles is understandable in the same way that enthusiasm for any promising early-phase compound is understandable. But promising pharmacokinetics and a single Phase I/II trial are not evidence that a compound works for the indications being claimed. Tesamorelin earned its approval by doing the hard work. CJC-1295 hasn’t, and the field would be better served by demanding that standard than by treating the 2006 Teichman data as a foundation it was never designed to be.
[1]: Teichman et al., J Clin Endocrinol Metab2006.
[2]: Falutz et al., Lancet HIV2019.
[3]: Frontiers in Aging review, 2026.
[4]: Translational Andrology and Urology review, 2020.
[5]: Nass et al., Ann Intern Med2008.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 2006.
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.. The lancet. HIV, 2019.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.. Frontiers in aging, 2026.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.. Translational andrology and urology, 2020.
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.. Annals of internal medicine, 2008.
